New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
06:31 EDTIMGNImmunoGen announces preclinical findings for IMGN779
In preclinical findings reported at EHA, IMGN779 demonstrated potent, targeted activity against primary AML patient cells in vitro. IMGN779 can selectively kill leukemic cells (blasts) while sparing normal hematopoietic stem cells. IMGN779 was found to be highly active against human AML xenografts in vivo, demonstrating potent and targeted activity. IMGN779 was well tolerated without delayed toxicity in animal models. IMGN779 is on track to become the companyís next wholly owned clinical-stage compound. ImmunoGen is preparing to submit the IMGN779 IND in mid-2015.
News For IMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
16:31 EDTIMGNOn The Fly: Closing Wrap
Subscribe for More Information
13:30 EDTIMGNImmunoGen downgraded to Market Perform from Outperform at Leerink
Leerink downgraded ImmunoGen to Hold following disappointing MARIANNE trial results.
13:16 EDTIMGNImmunoGen downgraded to Hold from Buy at Jefferies
Subscribe for More Information
12:27 EDTIMGNOn The Fly: Midday Wrap
Subscribe for More Information
09:28 EDTIMGNOn The Fly: Pre-market Movers
Subscribe for More Information
05:36 EDTIMGNImmunoGen reports Phase III MARIANNE study met non-inferiority endpoint
Subscribe for More Information
December 10, 2014
15:14 EDTIMGNImmunoGen volatility at high end of historic range
Subscribe for More Information
December 7, 2014
12:53 EDTIMGNImmunoGen announces 'encouraging' IMGN529 clinical data
ImmunoGen announced the presentation of encouraging clinical findings with its IMGN529 experimental therapy for B-cell malignancies at the American Society of Hematology annual meeting. These include objective responses at doses that were generally well tolerated. ImmunoGenís IMGN529 is a potential new treatment for DLBCL and other non-Hodgkin lymphoma, NHL, subtypes. An ADC, it comprises an antibody that targets CD37, found on B-cell malignancies, with the potent cancer cell-killing agent, DM1, attached. The antibody serves to deliver the DM1 specifically to B cells to kill them and, based on preclinical research, also contributes anticancer activity. IMGN529 is currently in the dose-finding portion of a Phase I clinical trial, which assesses increasing doses of this experimental therapy in new groups of patients with relapsed/refractory NHL. Findings with the first doses evaluated were reported previously.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use